AbbVie (ABBV) has submitted a New Drug Application to the FDA for tavapadon, a selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease. The submission is based on results from the TEMPO clinical development program. This included two Phase 3 trials - TEMPO-1 and TEMPO-2 - in early Parkinson's disease, and one Phase 3 trial - TEMPO-3 with tavapadon as adjunctive to levodopa in patients experiencing motor fluctuations. The submission is also based on an interim data cut from TEMPO-4, an open-label extension trial.
Roopal Thakkar, chief scientific officer, AbbVie, said: "We recognize the physical and mental impact that Parkinson's disease can cause and are committed to providing next-generation treatment options that will help individuals regain motor control and independence at all stages of this challenging disease."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.